CRISPR Screen Dataset
Manguso RT (2017) - 1-PMID28723893
Title: In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Screen Details:
- Screen Rationale : Tumorigenicity in presence of immunotherapy
- Cell Type : Melanoma Cell Line [BTO:0000849]
- Cell Line : B16-F10 [BTO:0002014, CELLOSAURUS:CVCL_0159]
- Phenotype : Tumorigenicity
- Condition : Immunotherapy (GVAX + PD-1 blockade)
- Library : CRISPRn Targeted Library (Haining, 2017) | Type: CRISPRn | Format: in vivo | Enzyme: Cas9 | Methodology: Knockout
- Analysis Method : STARS | Number of Hits: 62 | Full Dataset Size: 2,368
- Experimental Setup : Implantation to Mouse Model | Duration: 12 Days
- Significance : Authors have indicated that results with Score.3 (FDR) < 0.1 are to be considered significant. These results are indicated by '' in the HIT column of the table below.
Notes:
- sgRNAs that are significantly depleted from tumours treated with immunotherapy ( GVAX + PD-1 blockade) relative to TCRalpha KO mice which are unable to apply adaptive immune-selective pressure on the tumours, indicate that loss of the targeted gene increased the sensitivity of tumour cells to immune attack
- The immunotherapy consisted of animals injected with tumour cells being treated with a granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, irradiated tumour cell vaccine (GVAX) combined with PD-1 blockade using a monoclonal antibody against PD-1 to generate an adaptive immune response sufficient to apply immune-selective pressure on the tumour cells
Score Distribution
< 8.954121164
> 0.814070938